New drug aims to keep insulin flowing in early type 1 diabetes

NCT ID NCT07142252

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests an experimental drug called rezpegaldesleukin in people diagnosed with type 1 diabetes within the past 100 days. The goal is to see if the drug can help the body keep making its own insulin, reducing the need for injected insulin. About 66 participants will receive either the drug or a placebo every two weeks for 26 weeks, and their insulin production will be measured after one year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of British Columbia

    NOT_YET_RECRUITING

    Vancouver, British Columbia, V5Z4H4, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Vanderbilt University

    NOT_YET_RECRUITING

    Nashville, Tennessee, 37232, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.